Regenxbio Inc
Change company Symbol lookup
Select an option...
RGNX Regenxbio Inc
PCT Purecycle Technologies Inc
SGBXV Safe & Green Holdings Corp
GOOG Alphabet Inc
WHLR Wheeler Real Estate Investment Trust Inc
FRHLF Freehold Royalties Ltd
CTNT Cheetah Net Supply Chain Service Inc
LASE Laser Photonics Corp
GFR M3-Brigade Acquisition III Corp
UPST Upstart Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Closing Price
Day's Change
-0.51 (-2.89%)
B/A Size
Day's High
Day's Low

10-day average volume:



All providers
September 05, 2023
REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare ConferenceFireside Chat Date: Tuesday, September 12, 2023Fireside Chat Time: 10:10 a.m...(PR Newswire)

August 30, 2023
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

-- Six-month data from single-patient, investigator-initiated trial showed that one-time administration of RGX-181 was well tolerated, achieved sustained gene expression and demonstrated clinically meaningful improvements across multiple measures...(PR Newswire)

August 23, 2023
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 in Jerusalem, Israel (August 29 - September 1). Investigators will deliver encore presentations of interim...(PR Newswire)

August 02, 2023
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

-- Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 -- ABBV-RGX-314 program for the treatment of wet AMD and diabetic...(PR Newswire)

August 01, 2023
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, June 8, 2023. 2023 Wedbush PacGrow Healthcare ConferenceDate:Tuesday, August 8, 2023 (PR Newswire)

July 26, 2023
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent operational highlights. (PR Newswire)

July 24, 2023
REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting

REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking place in Seattle, Washington from July 28 through August 1, 2023. The presentations will...(PR Newswire)

July 11, 2023
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation Initial safety results from Cohort 1 of the AFFINITY DUCHENNE study...(PR Newswire)

June 27, 2023
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

REGENXBIO AAV Therapeutics pipeline to be discussed by management and external experts Focus on programs for Wet AMD, Diabetic Retinopathy, and Duchenne Muscular Dystrophy REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.